Unitedhealth Group Inc

Overall performance beat / upgraded outlook (good, surprising) - Adjusted EPS: $6.38 vs $4.08 in 2Q 2025 (+~56% YoY). - Operating earnings: $8B (+55% YoY). - Total revenues: $112B (roughly flat YoY). - Full-year 2026 guidance refreshed: Adjusted EPS range $19.50–$20.00 (slightly more EPS expected in 3Q vs 4Q). - Medical care ratio outlook: 88.1% ± 25 bps. - Management emphasized that the improved results reflect “stronger broad-based performance disciplines,” especially in Medicare and Optum Health.

UnitedHealthcare: Medicare strength offsets Commercial weakness (good + negative) - Medicare Advantage - 2Q strong; retention better than expected. - Full-year MA enrollment: now expected to decline ~1.1 million (vs prior expectations it was more negative), supporting margin resilience. - 2026 Medicare margins: expected to finish above 3%. - Medical cost trend: Medicare trend still above historical levels, but below the company’s initial ~10% estimate so far in 2026; they now expect 2026 Medicare medical cost trend below ~10%. - Medicaid - Q2 “in line with expectations.” - Company now expects 2026 Medicaid margins remain pressured, but should land within the previously communicated range of ~-1% to -1.7%. - Progress/early signs of improvement from initiatives (notably behavioral health cost pressures), but persistent elevated trend remains (especially specialty pharmacy, home/community-based services, behavioral healthcare, and some SNF inpatient cost pressure). - Commercial - Still the biggest drag. Medical cost trends running modestly above 11% (i.e., worse than their earlier expectation). - Key drivers: No Surprises Act (IDR) process inefficiencies exploited by some providers + more aggressive billing/coding intensity (office/ED and other higher service mix), plus pharmacy specialty drugs (anti-inflammatories, GLP-1s). - Commercial margin recovery seen as delayed: 2026 is more of a “delay” not “reset” to recovery; full recovery beyond 2027 timeframe.

Optum momentum continues; integrated value-based care re-focus (good) - Optum Health performing in line or ahead of plan in 1H 2026. - Reported examples of clinical/operational impact: - ~10% reduction in hospitalizations in Western & Southern regions (post late-2025 implementation). - >20% improvement in timely care delivery in pilots for home health initiatives + reduced acute utilization and shorter SNF stays. - Rural reach: Optum Health reaches ~90% of U.S. counties with ~2.5M rural patient home visits; expansion expected by end of 2026. - AI rollout progress: ambient listening available to 70% of employed providers, on track to exceed 90% by year-end. - Patient experience/access: ~5% YoY improvement; ~200,000 more patient-facing hours. - Optum Rx: on plan; transparency initiatives resonating; retention high 90s; continuing shift to fee-based + transparency (monthly per-member fee approach introduced; strong client feedback). - Optum Insight: on a multi-year reinvestment/innovation path, leveraging AI-enabled tools (e.g., Value Connect reported early results including 17% pharmacy cost reduction for clients).